Corcept (CORT) Q2 2025 Earnings Transcript

Corcept reported Q2 revenue of $194.4 million, up 18.7% year over year, while net income was roughly flat at $35.1 million. Management raised 2025 revenue guidance to $850 million-$900 million and highlighted strong prescription growth, but said pharmacy delays shaved about $15 million from quarterly revenue and continue to affect timing. The bigger catalyst is relacorilant, with a December 30 PDUFA date in hypercortisolism, an oncology NDA already submitted, and management projecting $3 billion-$5 billion in annual hypercortisolism revenue within 3-5 years.

Analysis

The core setup is not a one-quarter earnings beat; it is a step-function re-rating of the addressable market. CATALYST does two things simultaneously: it expands the diagnosed patient pool and it raises prescriber willingness to treat earlier, which should steepen the adoption curve into relacorilant approval rather than reset it. The commercial bottleneck is now operational, not clinical, so the next inflection is likely a Q4/Q1 revenue catch-up once pharmacy throughput normalizes and the second pharmacy contributes.

The market may be underestimating how much of the near-term upside is self-funded by the installed base. Because the AG transition has already compressed realized pricing, incremental demand can look weaker in reported revenue than in underlying patient starts; that creates a classic visibility trap where the business is growing faster than the P&L. In other words, the current pricing mix pain is a transition cost, but the backlog effect should show up later as a cleaner revenue ramp when fulfillment stops leaking.

The most asymmetric optionality remains the December PDUFA plus the Teva appeal. A favorable patent ruling would not change the growth thesis, but it would materially extend the duration of cash generation from the legacy asset just as relacorilant launches, reducing the odds that the market over-discounts the bridge period. The bigger contrarian point is that oncology is not just a sidecar: if ROSELLA data is repeatable in broader gynecologic settings, the street may be too anchored to endocrine economics and underpricing the platform value.

Main risks are binary and timing-driven: an FDA delay, an unexpected label limitation, or a generic/legal setback could compress multiple expansion before the relacorilant launch is proven in real-world adoption. On the other hand, the operating leverage is large because this is a specialty prescriber model with a fixed sales force that can absorb more volume without proportional opex. That makes the next 6-9 months the key window for upside capture, while the long-dated oncology expansion is a 12-24 month call option.

Key Decisions for Investors

• Long CORT into the December PDUFA window with a 3-6 month horizon; risk/reward is attractive if investors are underpricing relacorilant launch timing and the Q4 pharmacy normalization catch-up.
• Add to CORT on any post-earnings pullback tied to revenue guidance cut; the setup favors a backlog unwind trade rather than a demand deterioration story.
• Buy CORT Jan-2026 or Apr-2026 calls to express upside on both the FDA decision and Teva appeal; limited downside versus owning spot through two binary catalysts.
• Pair trade: long CORT / short TEVA over the next 2-4 months; if Corcept wins even partially, TEVA carries direct idiosyncratic downside while CORT gets duration extension on its cash flows.
• If CORT rallies sharply pre-PDUFA, consider monetizing part of the move and keeping a smaller call position for the oncology read-through, which is the higher-duration, lower-consensus upside.